

“GEFITINIB THE 1ST PERSONALIZED THERAPY THAT HAS CHANGED THE PARADIGM FOR THE PATHWAY OF NSCLC EGFR M+”.

Friday, 11 March 2011

Chairman: M. Reck (Hospital Grosshansdorf, Grosshansdorf, Germany)
Speakers: N. Normanno (INT Fondazione “G. Pascale,” Naples, Italy)
S. Novello (University of Turin, Orbassano, Italy)

AGENDA

18.10 - 18.15	Welcome and introduction	(M. Reck)
18.15 - 18.35	New paradigm in diagnosis	(N. Normanno)
18.35 - 18.55	New paradigm in treatment	(S. Novello)
18.55 - 19.10	Discussion and closing remarks	(M. Reck)

AstraZeneca 

SATELLITE SYMPOSIUM HELD IN CONJUNCTION WITH THE PERSPECTIVES IN LUNG CANCER: 12TH EUROPEAN CONGRESS

11-12 March 2011

Lingotto Conference and Exhibition Centre
Via Nizza 280
10126 Torino

SYMPOSIUM “GEFITINIB THE 1ST PERSONALIZED THERAPY THAT HAS CHANGED THE PARADIGM FOR THE PATHWAY OF NSCLC EGFR M+”.

Friday, 11 March 2011
Auditorium G. Agnelli

AstraZeneca 

SATELLITE SYMPOSIUM HELD IN CONJUNCTION WITH THE
PERSPECTIVES IN LUNG CANCER: 12TH EUROPEAN CONGRESS
SCIENTIFIC AGENDA - Friday, 11 March 2011

8.15 Welcome and introduction (G. V. Scagliotti, MD, PhD)

SESSION I: EPIDEMIOLOGY OF LUNG CANCER

8.30 Molecular epidemiology of lung cancer (P. Boffetta, MD)

8.50 Epigenetic changes in lung cancer (M. Sanchez-Cespedes, MD)

9.10 Lung cancer in never smokers: a new molecular and clinical entity (L. Crinò, MD)

9.30 Clinical case on new staging system for lung cancer (P. E. Postmus, MD, PhD)

SESSION II: KEYNOTE LECTURE

9.50 The c-met oncogene in human cancer (P. Comoglio, MD, PhD)

10.20 *COFFEE BREAK*

SESSION III: ENDOSCOPY, IMAGING AND PATHOLOGY IN LUNG CANCER

10.40 The spectrum of optics in the management of lung cancer (T. G. Sutedja, MD, PhD)

11.00 Minimally invasive surgical techniques for the diagnosis and treatment of lung cancer (G. Rocco, MD)

11.20 PET in lung cancer (O. S. Hoekstra, MD)

11.40 Hot topics in diagnostic pathology (E. Brambilla, MD)

12.20 Lunch Satellite Symposium: The evolving knowledge in the systemic treatment of NSCLC
Supported by Lilly

13.50 Symposium Adjourns

SESSION IV: THORACIC RADIATION THERAPY AND LUNG CANCER

14.00 Physical and biological basis of modern radiotherapy (P. van Houtte, MD)

14.20 Combining chemotherapy and radiotherapy in stage III NSCLC (R. Govindan, MD)

14.40 Targeted therapies and thoracic radiation therapy (U. Ricardi, MD, PhD)

15.00 Management of acute and chronic side effects of thoracic radiation therapy (C. Le Pechoux, MD)

15.20 Clinical case of combined modality therapy (P. van Houtte, MD)

15.40 *COFFEE BREAK*

SESSION V: TARGETED THERAPIES IN LUNG CANCER: WHAT HAVE WE LEARNED?

16.10 Insulin-like growth factor receptor (IGF-R1) inhibitors (L. Paz-Ares, MD, PhD)

16.30 VEGF-Multiple TKIs (M. Reck, MD)

16.50 c-MET and ALK inhibitors (R. Govindan, MD)

17.10 HDAC and PARP inhibitors (W. Eberhardt, MD)

17.30 Targeting cancer stem cells (R. De Maria, MD)

17.50 Wrap up of day one

18.00 Session Adjourn

18.10 Evening Satellite Symposium:
Gefitinib the 1st personalized therapy that has changed the paradigm for the pathway
of NSCLC EGFR M+
Supported by AstraZeneca
(M. Reck, N. Normanno, S. Novello)

19.10 Symposium Adjourns